A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Clinical trial NCT06220201 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06220201
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Sclerosis Myasthenia Gravis

Start date: 2024-03-28
Primary completion: 2027-07-15
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.